Worldwide, billions of people suffer from various pulmonary diseases and numbers are still growing. Presently, most studied biomedicine in treatment and pharmacotherapy of several pulmonary diseases are naturally occurring bioactive phytoconstituents. They have showed an unique potential with minimum adverse effects and great capacity to treat pulmonary diseases. Till date, numerous novel pulmonary delivery systems have been developed and studied to delivery bioactive phytoconstituents. Among them, dry powder inhalers (DPIs) are most prefered because of their better physicochemical stability and satisfactory lungs deposition using the patient’s respiration. This article represents an outlook on phytoconstituents based DPIs to understand pulmonary deliveries for its better functioning.

Pulmonary disease represents a major global health issue. They are commonly treated by various synthetic molecules. But, frequent high-dose of oral and injectable drugs may lead to severe side effects and this juncture demands inhaled formulations that facilitate effective drug delivery to the lower airways with negligible side effects. Natural phytoconstituents or phytoalexin (i.e. plant antibiotics) have showed an unique treatment array with minimum side effects and great capability to treat intrapulmonary and extrapulmonary diseases compared to synthetic drugs. Moreover, the progress of disciplines such as nanotechnology, material science and particle engineering allows further improvement of the treatment capability and efficiency. This article review and analyze literatures on inhaled phytoconstituents which were published in the last 10 years. Additionally, it will also offer the researcher with some basic background information for phytoconstituents profile, formulation requirements and drug delivery systems.